Evidence map›Paper›PMID 34073301›Full record

ArticleCancers2021

Refinement of an Established Procedure and Its Application for Identification of Hypoxia in Prostate Cancer Xenografts.

Pernille B Elming, Thomas R Wittenborn, Morten Busk, Brita S Sørensen, Mathilde Borg Houlberg Thomsen, Trine Strandgaard, Lars Dyrskjøt, Steffen Nielsen, Michael R Horsman

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Pernille B ElmingExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Thomas R WittenbornExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Morten BuskDanish Center for Particle Therapy, Aarhus University Hospital, 8200 Aarhus, Denmark.
Brita S SørensenExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.ORCID 0000-0002-3955-4735
Mathilde Borg Houlberg ThomsenDepartment of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
Trine StrandgaardDepartment of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.
Lars DyrskjøtDepartment of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark.ORCID 0000-0001-7061-9851
Steffen NielsenExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Michael R HorsmanExperimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Aarhus University Hospital · DKAarhus University · DK

Funding

Kræftens Bekæmpelse R40-A2022-11-S2Sundhed og Sygdom, Det Frie Forskningsråd DFF - 4004-00362
6 · The paper itself

Abstract

backgroundThis pre-clinical study was designed to refine a dissection method for validating the use of a 15-gene hypoxia classifier, which was previously established for head and neck squamous cell carcinoma (HNSCC) patients, to identify hypoxia in prostate cancer.

methodsPC3 and DU-145 adenocarcinoma cells, in vitro, were gassed with various oxygen concentrations (0-21%) for 24 h, followed by real-time PCR. Xenografts were established in vivo, and the mice were injected with the hypoxic markers [18F]-FAZA and pimonidazole. Subsequently, tumors were excised, frozen, cryo-sectioned, and analyzed using autoradiography ([18F]-FAZA) and immunohistochemistry (pimonidazole); the autoradiograms used as templates for laser capture microdissection of hypoxic and non-hypoxic areas, which were lysed, and real-time PCR was performed.

resultsIn vitro, all 15 genes were increasingly up-regulated as oxygen concentrations decreased. With the xenografts, all 15 genes were up-regulated in the hypoxic compared to non-hypoxic areas for both cell lines, although this effect was greater in the DU-145.

conclusionsWe have developed a combined autoradiographic/laser-guided microdissection method with broad applicability. Using this approach on fresh frozen tumor material, thereby minimizing the degree of RNA degradation, we showed that the 15-gene hypoxia gene classifier developed in HNSCC may be applicable for adenocarcinomas such as prostate cancer.

Indexed as

DU-145hypoxiahypoxia gene signaturePC3pre-clinical modelsprostate cancer

Identifiers

PMID34073301
PMCPMC8198481
OpenAlexW3165364260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.